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Meilan Chen, Jizheng Huang, Zhenli Zhu, Jun Zhang and Ke Li*Abstract
Background: Esophageal cancer (EC) is a frequently occurring cancer with poor prognosis despite combined
therapeutic strategies. Many biomarkers have been proposed as predictors of adverse events. We sought to assess
the prognostic value of biomarkers in predicting the overall survival of esophageal cancer and to help guide
personalized cancer treatment to give patients the best chance at remission.
Methods: We conducted a systematic review and meta-analysis of the published literature to summarize evidence
for the discriminatory ability of prognostic biomarkers for esophageal cancer. Relevant literature was identified using
the PubMed database on April 11, 2012, and conformed to the REMARK criteria. The primary endpoint was overall
survival and data were synthesized with hazard ratios (HRs).
Results: We included 109 studies, exploring 13 different biomarkers, which were subjected to quantitative meta-analysis.
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF
(18 eligible studies, n = 1476, HR = 1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n = 1476, HR = 1.82, 95% CI,
1.50-2.20), Ki-67 (3 eligible studies, n = 308, HR = 1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen
(5 eligible studies, n = 700, HR = 1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma
included COX-2 (2 eligible studies, n = 235, HR = 3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n = 291,
HR = 2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n = 858,
HR = 1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n = 2851, HR = 1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies,
n = 1382, HR = 2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n = 544, HR = 0.91, 95% CI, 0.83-1.00).
Conclusions: Although some modest bias cannot be excluded, this review supports the involvement of
biomarkers to be associated with EC overall survival.
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Esophageal cancer (EC), which accounted for 482,300
new cases of cancer in 2008, is the eighth most common
cancer worldwide, and has the sixth highest incidence of
cancer mortality, with 406,800 deaths registered [1]. Al-
though the prevalence is highest in Africa and Asia, the
incidence of adenocarcinoma is rising in western countries
and the America [2-4]. Surgery, combined with neoadju-
vant radiation and chemotherapy, or even neoadjuvant
chemoradiotherapy, remains the only curative modality for* Correspondence: kli@stu.edu.cn
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reproduction in any medium, provided the orEC. However, the long-term prognosis of patients undergo-
ing potentially curative esophageal resection is still poor,
with the reported 5-year survival rate being 9.8% [5].
Commonly used classification systems utilize histological
type to group EC into two main categories: esophageal
squamous cell carcinoma (ESCC) and adenocarcinoma
(EADC). ESCC can occur in all parts of the esophagus,
whereas EADC arises mostly via metaplasia of the epithe-
lium of the distal esophagus. Published studies of EC may
not distinguish between ESCC and EADC.
The ability to predict patients with poor prognosis
would help guide surgery and adjuvant treatment ac-
cording to individual risk. Attempts have been made totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathological characteristics. Age, tumor stage distribu-
tion, tumor histology and body mass index have all been
found to predict survival [6-8]. The ability to predict
tumor behavior on the basis of molecular markers from
either biopsy or serum samples would help inform the pa-
tients and clinician during the decision-making process.
With advances in the understanding of tumor biology,
there is sufficient new evidence available to gain further
insight into this disease. In addition, biomarkers of prog-
nostic significance, may present novel therapeutic targets.
The aim of this study was to summarize the results of
published studies regarding the prognostic role of the
molecular markers in EC. In this review, we prioritized
the available data, in all included surveys, according to
either the REMARK (Reporting recommendations for
tumor MARKer prognostic studies) study design or meth-
odological assessment quality metrics [9]. Many variations
exist in the experimental methods chosen and procedures
used, including antigen retrieval observed variability in
staining pattern description, cut-off point selection, and as-
signment of specimens to categories, that influence the
prognostic value of the proposed association. Because new
biomarkers should enhance the current routine prognostic
markers to be adopted for use in the clinic, studies that do
not extend their statistical analysis beyond univariate sur-
vival measures are less valuable than studies that do. We
sought to determine candidate biomarkers with sufficient
evidence to support prospective validation in a controlled
clinical environment and to identify functional pathways
for which data either suggest a lack of involvement in EC
prognosis or the need for additional investigation due to
insufficient rigor among the previously conducted studies.
We identified a subset of candidate predictors of EC out-
come from the published literature that were evaluated ac-
cording to robust sampling and laboratory methods.
Methods
Search strategy
To identify all primary research studies that evaluated
levels of candidate biomarker expression as a prog-
nostic factor among individuals with EC, we searched
the PubMed medical literature database up to April 11,
2012, without language restrictions, using a strategy de-
veloped with an expert librarian based on terms for
esophageal carcinoma, prognostic studies [10] and bio-
markers. The search strategy was based on combina-
tions of (“esophageal” or “esophagus”), (“neoplasms” or
“carcinoma” or “tumor”), (gene or protein or biomarker
or marker), and (prognos* or “survival analysis” [Mesh]
or “follow-up studies” [Mesh] or mortality [Majr] or
mortality[subheading] or incidence [Mesh] or predict or
course or outcome). One reviewer (M. Chen) ob-
tained the full texts of relevant articles following thesearch and inspection of titles and abstracts of citations
to identify those articles that were likely to report the study
of prognostic biomarkers in EC. In cases where data in sev-
eral publications were derived from part or all of the same
patient series, only the study presenting the most recent or
most complete dataset was included.
Methodology and validity assessment
We used published guidelines for reporting tumor marker
studies and quality metrics for evaluating studies to in-
clude in the cancer-related meta-analyses [9,11]. Criteria
used to determine study eligibility were as follows: 1) a
prospective or retrospective cohort design with a well-
defined study population and justification for all excluded
eligible cases, 2) assay of the primary EC specimens, 3) a
clear description of methods for specimen handling and
testing, including selection and preparation of reagents or
kits, as well as visualization techniques, 4) clear statements
on the choice of positive/present and negative/absent con-
trols and on assay validation, 5) statistical analysis using
multivariable proportional hazards modeling that adjusted
for clinical prognostic factors, and 6) reporting of the re-
sultant adjusted hazard ratios (HRs) and their 95% confi-
dence intervals (CIs), or provision of data available for
statistical estimation of HRs. Because esophageal small cell
carcinomas, epidermoid cancer of the esophagus, and
neuroendocrine carcinoma of the esophagus have differ-
ent clinical courses, studies that did not distinguish these
tumor types from EC were excluded.
Quality assessment was performed in duplicated for
each eligible study by two independent reviewers (Chen
and Huang) using operationalized prognostic biomarker
reporting guidelines [9] and extract details on 16 items
(Additional file 1: Table S1). This scale allowed for as-
sessment of study design, biomarker measurement, out-
come and analysis.
Data extraction
Two investigators (Chen and Zhu) reviewed all eligible
studies and carefully extracted study characteristics in
duplicate, including the first author’s name, publication
year, country of origin, histology, sample size, gender,
mean/median age, disease stage, test method, cutoff value,
the status of biomarker expression, and the computed mul-
tivariable hazard ratio and its 95% CI. When results were
present without confidence intervals, the p value was used
to estimate the confidence intervals via the z-statistic.
Statistical methods
All eligible individual biomarker assays were sorted ac-
cording to their major biological function. Function was
determined by reviewing the current scientific literature
comprehensively and then classifying according to the 5
acquired capabilities of cancer as defined by Hanahan
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genesis, evasion of apoptosis, insensitivity to antigrowth
signals, limitless replicative potential and tissue invasion
and metastasis. To accommodate blood biomarkers,
the Hanahan-Weinberg classification system was sup-
plemented by one additional category: serum markers.
Biomarkers evaluated in less than five studies, were ex-
cluded in this review and out of quantitative synthesis. For
biomarkers assayed in five or more studies, the summary
HR and 95% CI were calculated by using fixed effects ac-
cording to generic inverse variance and random effects
model using the DerSimonian-Laird method [13]. Statis-
tical heterogeneity among studies was assessed using Q
and I2 statistics [14]. We considered that heterogeneity
was present when the Q-test P-value was less than 0.1. In
addition, when I2 was lower than 50%, studies with an ac-
ceptable heterogeneity were considered, and the fixed-
effects model was used; otherwise, a random effect model
was adopted. The combined HRs were estimated graphic-
ally by Forest plots. Possible source of heterogeneity were
investigated by subgroup analysis. Study publication bias
was assessed with counter-enhanced funnel plots, by
Begg’s adjusted rank correlation test and by Egger’s regres-
sion asymmetry test [15-17]. When p > 0.05 was consid-
ered to indicate that there was no publication bias in the
studies. All statistical analysis was conducted using Stata
SE 11.0 software (Stata Corporation).
Results
Eligible studies
The abstracts and titles of 3259 primary manuscripts
were identified for initial review using strategies as de-
scribed. Reviewers identified 979 manuscripts to be appro-
priate in terms of evaluation of prognostic biomarkers in
EC. For these manuscripts, full-text articles were obtained.
Upon further review, 109 studies published between 1994
and 2012 were eligible for this systematic review and with
meta-analysis (Figure 1).
All reported the prognostic value of biomarkers in
patients with EC by presenting multivariable survival
estimates for differential levels of candidate biomarker
expression. Effective sample size ranged from 29 [18] to
708 patients [19] (median, 87 patients), with 13 studies
including 50 or fewer patients, 54 studies including 51-
100 individuals, 26 studies including 101-150 individuals,
12 studies including 151-300 individuals and 4 studies in-
cluding more than 300 individuals. Seventeen clinico-
pathologic factors were incorporated in one or more of
the eligible studies’ multivariate analysis. The most com-
monly included prognostic factor was depth of invasion
involvement with lymph node status being included in 67
(61%) studies and 65 (59%) studies. Other common ad-
justment parameters included tumor stage (37 of 109
studies), gender (27 of 109 studies) and metastatic status(27 of 109 studies) (Figure 2A). Fifty-seven studies
considered three to five clinical parameters in their multi-
variable proportional hazards models, 26 studies consid-
ered less than three covariates, 21 studies included more
than five covariates and another 5 studies did not report
(Figure 2B).
These 109 studies presented data on 13 unique bio-
markers. The majority of eligible studies (n = 87) restricted
their analysis to a single included candidate marker, and
the remaining 22 evaluated between two to five markers.
Regarding angiogenesis, 6 studies of cyclooxygenase-2
(COX-2) [20-25] and 19 studies of vascular endothelial
growth factor (VEGF) [26-44] were included. Of the
eligible marker associated with apoptosis, 5 studies of
survivin [45-49] were available for analysis. For cell-
cycle regulators, 9 studies of p21 [27,50-57] and 7 studies
of p27 [25,58-63] were included. Four markers asso-
ciated with replicative potential were eligible for examin-
ation, and were comprised of 15 studies of cyclin D1
[27,51,54,58,59,62,64-72], 32 eligible studies of p53
[27,30,32,34,38,40,51,54,68,73-95], 6 studies of human
epidermal growth factor receptor-2 (HER-2) [19,96-100]
and 5 studies of Ki67 [25,27,87,101,102]. Regarding the tis-
sue invasion and metastasis markers evaluated, 10 studies
of E-cadherin [27,65,102-109] were included. Three eligible
serum markers were eligible for analysis, and were com-
prised of 8 studies of C reative protein (CRP) [110-117],
5 studies of SCC-Ag [18,118-121] and 5 studies of
hemoglobin (Hb) [122-126]. The 13 biomarkers were
evaluated for overall survival (OS) and sorted according
to five to eight Hanahan-Weinberg functional capabilities
modified to include serum markers (Additional file 2:
Table S2). Additional file 2: Table S2 outlines the demo-
graphic, clinicopathological, methodological and outcome
characteristics of these studies.
Quality of study reports
The mean number of study quality items reported was
11 out of possible 16 and was not associated with sample
size with correlation coefficient of 0.06, p = 0.52 (Figure 3).
There was also no statistically significant difference be-
tween the quality items of 65 positive studies (where a bio-
marker was statistically a factor for poor prognosis) and 44
negative studies (where a biomarker was not statistically
significant) (Mann-Whitney p = 0.27). All of the studies re-
ported details of the clinical endpoint and multivariate ana-
lysis. More than 90% of studies reported details of the
objective or prespecified hypothesis, patient source, popu-
lation characteristics, assay method, manufacturer, cutpoint
and confounders. Of note, 63 studies reported the follow-
up period or the median follow-up time. One study re-
ferred to a missing value, but no study referred to a statis-
tical sample size. To try to evaluate the impact of study
quality on the final pooled estimate, a subgroup analysis
PubMed search strategy run on April 
11st, 2012
3259 manuscripts
2280 excluded after title/abstract review:
1627 no usable data reported
333 not esophageal cancers
248 review articles, conference, comments
36 about genetic polymorphism
36 not human studies
Full texts for 979 potential manuscripts 
retrieved for detailed evaluation
591 excluded after full-text review:
364 univariate statistics 
221 did not report HRs
6 duplicated publications
388 manuscripts collectively describing 
267 molecules
279 excluded:
272 studies excluded when the unique 
molecule was analyzed in less than five studies
7 studies with the same patient series
109 studies describing 13 molecules 
included for quantitative synthesis
Figure 1 Flow diagram of the literature search and selection of eligible studies.
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ity items: eleven or more eleven, which is the mean num-
ber of study quality items, and less than eleven. For
majority markers, the results were consistent, the pooled
HRs were not significantly altered, suggesting the study
quality improbable as source of bias. For COX-2, only one
study with quality items less than eleven, the HR was re-
ported 2.34 (95% CI, 1.11-4.91). The pooled HR estimated
for the other five studies was 1.36 (95% CI, 0.60-3.08),
which is similar to the final pooled HR 1.54 (95% CI, 0.80-
2.98). For HER-2, both subgroups included three studies
eligible for meta-analysis, with combined HR 1.64 (95%
CI,1.07-2.51) and 1.26 (95% CI, 0.70-2.26), respectively.
Because of a small number of studies included, the results
should be treated with caution.
Meta-analysis results for biomarkers
For the 13 markers, a multivariate HR and 95% CI were
available from five or more studies and were combined
using both fixed effects general inverse variance and
DerSimonian-Laird random effects modeling to obtain a
single summary HR and 95% CI. (Table 1) Five of the six
original Hanahan-Weinberg functional capabilities alongwith the additional group were represented by at least
one marker statistically associated with OS. Two studies
[35,91] were excluded which failed to present validated
data in their meta-analysis.
COX-2, VEGF
Of the six studies that used immunohistochemistry
(IHC) for OS data, the pooled HR was 1.54 (95% CI,
0.80-2.98), with significant evidence of heterogeneity be-
tween the contributing studies (I2 = 75%). Restricting
analysis to the four studies assessing COX-2 expression
in ESCC, the pooled HR was 0.96 (95% CI,0.39-2.41),
again, with evidence of study heterogeneity (73.5%). These
results should, however, be interpreted with caution be-
cause of the small number of contributing studies and the
significant evidence for significant study heterogeneity.
Two studies assessed COX-2 expression in EADC dis-
played a pooled HR of 3.06 (95% CI, 2.01-4.65), with no
evidence of heterogeneity (I2 = 0.0).
Of the eighteen VEGF expression studies eligible for
pooling of OS data, the pooled HR was 1.80 (95% CI,
1.51-2.14) with no evidence of heterogeneity. The For-
rest plot for this analysis is shown in Figure 4A. When
Figure 2 Characteristics of included studies in the systematic review. A. Frequencies with which adjustments were made for various
clinicopathologic parameters. B. Distributions of the total number of clinicopathologic covariates that were adjusted for across the 109 eligible
studies. NOTE: nr, not report.
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VEGF expression in ESCC, the combined HR was 1.85
(95% CI, 1.55-2.21) with no evidence of heterogeneity. Of
the other two studies, one presented data on EC and one
on EADC, respectively. To assess the effect of four
methods on evaluating VEGF expression, we pooled HRs
from studies using IHC, enzyme-linked immunosorbent
assay (ELISA) or reverse transcription polymerase chain
reaction (RTPCR). ELISA-based studies demonstrated a
larger pooled HR (HR 2.55, 95% CI, 1.72-3.79) compared
to IHC-based studies (HR 1.59, 95% CI, 1.28-1.98) or
RTPCR-based (HR 1.90, 95% CI, 1.24-2.91) studies.
Survivin
For five studies evaluating survivin expression in esopha-
geal cancers, the combined HR was 1.90 (95% CI, 1.06-
3.40) and there was evidence for heterogeneity (I2 =
74.6%). The pooled HR estimated for survival in the four
IHC-based studies involving ESCC was 1.57 (95% CI,
0.91-2.69), again, with significant evidence of heterogeneity
(I2 = 70.7%). The remaining PCR-based study involved EC,
and had an HR of 6.60 (95% CI, 1.97-22.12).p21, p27
Nine studies examined p21 and seven studies assessed
p27 levels with the pooled HRs of 1.27 (95% CI, 0.75-
2.16) and 1.68 (95% CI, 0.90-3.12), respectively, and
there was evidence of heterogeneity within both groups.
All studies used IHC to estimate the correlation between
biomarker expression and survival. Interestingly, when
grouped according to the histology of individual studies,
the combined HR in ESCC for p21 (seven studies), re-
mained unchanged at 1.28 (95% CI, 0.70-2.33). The pooled
HR for p27 (six studies) in ESCC was 1.97 (95% CI, 1.00-
3.88). In both analyses, there was significant evidence of
study heterogeneity (I2 = 87.4% for p21 and I2 = 74.6% for
p27, respectively).
Cyclin D1, HER-2, Ki-67, p53
Fifteen studies assessed cyclin D1. The overall pooled
HR was 1.73 (95% CI, 1.34-2.23) and there appeared to
be some heterogeneity between the studies (I2 = 56.3%)
Figure 4B illustrates the Forrest plot for the pooled data.
In subgroup analysis, the pooled HR for ESCC was 1.82
(95% CI, 1.50-2.20) with no evidence of heterogeneity.
Figure 3 Quality of individual study reports (n = 16 items, n = 109 studies), based on the REMARKER guidelines. Definition items of each
item are given in Additional file 1: Table S1.
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luable for assessment of EC and the pooled HR was
1.18 (95% CI, 0.57-2.45). However, this result should
be interpreted with caution because of the small number
of contributing studies and evidence for significant study
heterogeneity (I2 = 77.4%). To assess the effect of the
method used to assess cyclin D1 expression, HRs, using
either IHC or PCR, were pooled. This presented a large
pooled HR for PCR-based studies (HR 2.62, 95% CI,
1.41-4.89) compared to that from the IHC-based studies
(HR, 1.64, 95% CI, 1.26-2.14). The IHC-based group dis-
played significant heterogeneity, whereas the PCR-based
group did not.
Six studies examined the HER-2 as a biomarker. When
conducting subgroup analysis, we found three of six eli-
gible studies assessed HER-2 expression in EADC and
had a pooled HR of 2.15 (95% CI, 1.39-3.33) with no evi-
dence of heterogeneity. Two studies assessed HER-2 ex-
pression in an EC setting with a pooled HR of 0.91 (95%
CI, 0.73-1.12). Another study examined HER-2 in ESCC
and reported an HR of 0.92 (95% CI, 0.35-2.41). Because
of the small number of studies included, the results
should be treated with caution.
Three of five studies eligible for assessing Ki-67 in
ESCC demonstrated a pooled HR of 1.11 (95% CI, 0.70-
1.78) with no significant of heterogeneity. None of the
HR reported were statistically significant except in one
study that assessed in EADC and reported an HR of 0.26
(95% CI, 0.11-0.60).Thirty-one studies assessed p53. The pooled HR of
1.34 (95% CI, 1.21-1.48) revealed significant association
with overall survival and the Forest plot for this analysis
is shown in Figure 4C. Restricting analysis to the twenty
studies assessing p53 expression in ESCC gave a pooled
HR of 1.26 (95% CI, 1.11-1.42), with ELISA-based stud-
ies giving a larger pooled HR (2.13, 95% CI, 1.46-3.09)
than IHC-based studies (HR, 1.25, 95% CI, 1.12-1.40).
E-cadherin
Ten studies assessing the E-cadherin biomarker dis-
played a pooled HR of 1.13 (95% CI, 1.06-1.21) with evi-
dence of heterogeneity (Forrest plot in Figure 4D).
When restricting analysis to the seven studies examing
E-cadherin in ESCC, however, the result remained un-
changed, with an HR of 1.12 (95% CI, 1.05-1.19), again,
with significant heterogeneity. For the two studies asses-
sing E-cadherin expression in EC, the pooled HR was
1.41 (95% CI, 1.05-1.89), and there appeared to be no
heterogeneity between the studies. An EADC study re-
ported an HR of 3.30 (95% CI, 0.99-10.99). When grouped
according to method, the combined HR of IHC-based
studies was 1.28 (95% CI, 1.11-1.49) with significant het-
erogeneity. The only ELISA-based study reported an HR
of 1.10 (95% CI, 1.02-1.18).
SCC-Ag, CRP, Hb
Five eligible studies assessed SCC-Ag expression by en-
zyme immunoassay (EIA) in ESCC, and the pooled HR
Table 1 Summary of the multivariable hazard ratios and 95% CI for eligible biomarkers, organized according to the
Hanahan-Weinberg functional capability
Biomarker Group No. of studies Patients I-V HR(95% CI) D + L HR(95% CI) I2(%)
Angiogenesis
COX-2 Total(IHC) 6 469 2.00(1.47-2.71) 1.54(0.80-2.98) 75.0
ESCC 4 234 1.23(0.79-1.93) 0.96(0.39-2.41) 73.5
EADC 2 235 3.06(2.01-4.65) 3.06(2.01-4.65) 0.0
VEGF Total 18 1476 1.80(1.51-2.14) 1.76(1.38-2.24) 43.5
ESCC 16 1329 1.85(1.55-2.21) 1.84(1.45-2.33) 38.4
EADC 1 38 0.37(0.10-1.40) 0.37(0.10-1.40) -
EC 1 109 1.80(0.70-4.65) 1.80(0.70-4.65) -
IHC 14 1109 1.59(1.28-1.98) 1.56(1.16-2.12) 43.6
ELISA 2 179 2.55(1.72-3.79) 2.67(1.57-4.54) 36.8
RTPCR 2 188 1.90(1.24-2.91) 1.90(1.24-2.91) 0.0
Evading apoptosis
survivin Total 5 357 1.60(1.23-2.07) 1.90(1.06-3.40) 74.6
ESCC(IHC) 4 295 1.50(1.15-1.95) 1.57(0.91-2.69) 70.7
EC(PCR) 1 62 6.60(1.97-22.12) 6.60(1.97-22.12) -
Insensitivity to antigrowth signal
p21 Total(IHC) 9 858 0.90(0.75-1.08) 1.27(0.75-2.16) 86.4
ESCC 7 683 0.90(0.74-1.09) 1.28(0.70-2.33) 87.4
EC 2 175 0.94(0.57-1.53) 1.31(0.22-7.98) 91.2
p27(-) Total(IHC) 7 606 1.44(1.07-1.92) 1.68(0.90-3.12) 76.4
ESCC 6 478 1.75(1.25-2.44) 1.97(1.00-3.88) 74.6
EC 1 128 0.75(0.41-1.38) 0.75(0.41-1.38) -
Limitless replicative potential
cyclin D1 Total 15 1931 1.65(1.41-1.93) 1.73(1.34-2.23) 56.3
ESCC 12 1295 1.82(1.50-2.20) 1.89(1.44-2.48) 46.2
EC 3 636 1.37(1.05-1.80) 1.18(0.57-2.45) 77.4
IHC 13 1735 1.60(1.36-1.88) 1.64(1.26-2.14) 57.9
PCR 2 196 2.62(1.41-4.89) 2.79(1.27-6.14) 18.5
HER-2 Total 6 1162 1.06(0.88-1.28) 1.37(0.91-2.07) 67.6
ESCC 1 66 0.92(0.35-2.41) 0.92(0.35-2.41) -
EADC 3 291 2.15(1.39-3.33) 2.15(1.39-3.33) 0.0
EC 2 805 0.91(0.73-1.12) 0.93(0.70-1.23) 32.3
IHC 4 951 0.96(0.78-1.17) 1.17(0.72-1.88) 66.3
FISH 1 124 1.80(0.90-3.60) 1.80(0.90-3.60) -
RPPA 1 87 1.97(1.01-3.83) 1.97(1.01-3.83) -
Ki-67 Total(IHC) 5 424 0.84(0.59-1.20) 0.76(0.41-1.42) 62.2
ESCC 3 308 1.11(0.70-1.78) 1.11(0.70-1.78) 0.0
EADC 1 59 0.26(0.11-0.60) 0.26(0.11-0.60) -
EC 1 57 1.03(0.49-2.17) 1.03(0.49-2.17) -
P53 Total 31 2851 1.34(1.21-1.48) 1.33(1.14-1.56) 48.7
ESCC 20 2063 1.26(1.11-1.42) 1.25(1.03-1.51) 48.7
EADC 2 97 2.10(1.10-4.03) 2.10(1.10-4.03) 0.0
EC 9 691 1.53(1.25-1.86) 1.44(1.06-1.94) 50.9
Chen et al. BMC Cancer 2013, 13:539 Page 7 of 15
http://www.biomedcentral.com/1471-2407/13/539
Table 1 Summary of the multivariable hazard ratios and 95% CI for eligible biomarkers, organized according to the
Hanahan-Weinberg functional capability (Continued)
IHC 22 2122 1.25(1.12-1.40) 1.20(1.02-1.40) 38.5
PCR-SSCP 5 383 1.75(1.24-2.49) 1.82(0.93-3.56) 70.5
ELISA 4 346 2.13(1.46-3.09) 2.13(1.46-3.09) 0.0
Tissue invasion and metastasis
E-cadherin(-) Total 10 1569 1.13(1.06-1.21) 1.30(1.07-1.58) 61.8
ESCC 7 977 1.12(1.05-1.19) 1.24(0.99-1.56) 67.2
EADC 1 59 3.30(0.99-10.99) 3.30(0.99-10.99) -
EC 2 533 1.41(1.05-1.89) 1.41(1.05-1.89) 0.0
IHC 9 1472 1.28(1.11-1.49) 1.39(1.08-1.80) 60.4
ELISA 1 97 1.10(1.02-1.18) 1.10(1.02-1.18) -
Serum markers
SCC-Ag Total(ESCC/EIA) 5 700 1.28(0.97-1.69) 1.28(0.93-1.76) 16.4
Total 8 1382 1.43(1.27-1.61) 2.65(1.64-4.27) 85.8
ESCC 3 260 2.05(1.33-3.17) 2.77(1.12-6.86) 68.4
EC 5 1122 1.39(1.23-1.57) 2.66(1.44-4.92) 90.1
LPIA 1 262 3.30(2.17-5.01) 3.30(2.17-5.01) -
IHC 2 110 4.33(2.02-9.24) 4.33(2.02-9.24) 0.0
ELISA 1 150 1.42(0.83-2.42) 1.42(0.83-2.42) -
CRP-kit 1 356 1.52(1.05-2.21) 1.52(1.05-2.21) -
LEHIA 1 291 1.18(1.03-1.36) 1.18(1.03-1.36) -
INA 1 123 12.12(3.45-42.57) 12.12(3.45-42.57) -
ITA 1 90 5.07(1.92-13.41) 5.07(1.92-13.41) -
Total 5 544 0.96(0.95-0.98) 0.91(0.83-1.00) 87.1
ESCC 2 351 0.54(0.40-0.74) 0.54(0.40-0.74) 0.0
EC 3 193 0.97(0.95-0.98) 0.96(0.89-1.03) 88.3
NOTE: HR, hazard ratio; CI, confidence interval. Combined HRs are calculated for the fixed effects general inverse variance (I-V) method and random effects model
with DerSimonian and Laird (D + L) method. (-), reduced/negative expression show the higher risk in prognosis. IHC, immunohistochemistry; PCR, polymerase chain
reaction; SSCP, single-strand conformation polymorphism; ELISA,enzyme-linked immunosorbent assay; LPIA, latex photometric immunoassay; LEHIA, latex-enhanced
homogeneous immunoassay; INA, immunonephelometry; ITA, immunoturbidimetry; RIA, radioimmunoassay; EIA, enzyme immunoassay.
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heterogeneity. Eight studies examined CRP expression
with pooled HR 2.65 (95% CI, 1.64-4.27) and there was
a significant heterogeneity. When conducted subgroup
analysis, both EC and ESCC group still showed evidence
of heterogeneity. When grouped according to different
method used to assess CRP expression, two IHC-based
studies had pooled HR 4.33 (95% CI, 2.02-9.24). Other
studies used different method reported HR revealing a
significant association with poor survival but one ELISA-
based study (HR, 1.42, 95% CI, 0.83-2.42).
Five studies assessed Hb. The pooled HR was 0.91
(95% CI, 0.83-1.00) with significant heterogeneity. When
restricting analysis to the three studies assessing Hb
levels in EC, the pooled HR was 0.96 (95% CI, 0.89-
1.03), again, with evidence of heterogeneity. Two studies
assessing Hb levels in ESCC gave a pooled HR of 0.54
(95% CI, 0.40-0.74) with no evidence of heterogeneity.Only one included study reported no significant associ-
ation with outcome. However, data were not sufficient
to determine the prognostic value of Hb expression in
either ESCC or EADC.
Sensitivity analyses
We performed sensitivity analyses, in which one study
was removed at a time, to evaluate the result stability.
For COX-2, VEGF, cyclin D1, p53, E-cadherin and SCC-
Ag, the results indicated that fixed-effects estimates and/
or random effects estimate before and after the deletion
of each study were similar at large, suggesting high sta-
bility of the meta-analysis results. For survivin and CRP,
although the results are consistent with the overall
pooled estimates, the influencing single study conducted
by S. Mega et al. and Ines Gockel et al. respectively. For
other markers, the sensitivity analysis did not indicate
high stability of the results due to one or two studies.
Figure 4 Forest plots of the data for four biomarker-outcome comparisons for which eligible data were presented in ten or more studies.
Forest plots of HR for OS of (A) VEGF, (B) cyclin D1, (C) p53 and (D) E-cadherin. For each study, the hazard ratio (HR), 95% confidence interval (CI), and
relative weight are show. Combined fixed effect HRs and tests for heterogeneity (I2) were based on the generic inverse variance (I-V) method. Combined
random effect HRs were calculated according to the DerSimonian-Laird (D + L) method.
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the subgroup analysis results.
Publication bias
Begg’s test and Egger’s test were used to examine publica-
tion bias. There was evidence for significant publication
bias with p21 (Egger’s test p = 0.040), HER-2 (Egger’s test
p = 0.042) and CRP (Egger’s test p = 0.005).
Discussion
In response to the need for independent prognostic bio-
markers for EC that are readily evaluated on routinely
acquired clinical specimens, we performed a systematic
review and meta-analysis of the published EC literature
to identify the molecular markers for which the data
support validation as prognostic biomarkers of EC out-
come. Using stringent inclusion and exclusion criteria,
examining patient selection, and evaluating both la-
boratory and statistical methodology [9], we identi-
fied 109 high-quality studies describing multivariate
survival analysis for 13 unique biomarkers. Individual
biomarker assay data were organized according to OS,
and according to the Hanahan and Wernberg functionalgroupings that reflect the acquired capabilities of cancer
as defined [12].
Quality assessment tools have been developed for
prognostic studies to help identify study bias and causes
of heterogeneity when performing meta-analysis. We
chose to use and operationalize the REMARK reporting
guidelines, which provide a useful start for assessing
tumor prognostic biomarkers. We find that the studies re-
ported an average of 11 of 16 quality items. Comparison
of the quality items of positive and negative studies show
no statistically significant difference, allowing meaningful
data aggregation. Although this is a relatively new tool, it
has been used in other system reviews [127,128].
We demonstrate that COX-2 and VEGF, regulators of
angiogenesis, influence overall mortality, indicating the
importance of this functional grouping in EC progres-
sion. Elevated COX-2 levels may be associated with
worse outcome in EADC. Results in the present study
demonstrate that, because variability between studies as
to be the relative prognostic impact of COX-2 expression
in ESSC, the observed survival trend in EADC is con-
cordant with that reported for other malignancies [129].
Because VEGF is a heavily studied marker, the combined
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This result is concordant with existing reports, which im-
plicate a similar prognostic value for VEGF expression in
other malignancies [130,131], and lends further weight to
the assertion that angiogenesis is a key determinant in
driving EC progression.
Survivin, a strong negative regulator of apoptosis, in-
hibits or prevents the activation of caspases and promotes
cellular survival under otherwise apoptotic conditions
[132]. Elevated levels of survivin are significantly associated
with poor outcome in multiple studies, as judged by a ran-
dom effect model.
Cyclin-dependent kinase inhibitors (CKIs) block G1/S
phase transition, and decreased expression is thought to
result in deregulated growth, promoting tumor progres-
sion [133]. Reduced expression of p27 has been shown
to be a negative prognostic factor in many malignancies
[134]. In the six studies included here, the combined HR
demonstrates a significant association between decreased
p27 and poor prognosis in ESCC. In contrast, we did not
find expression of p21, a p53-inducible universal CKI, to
be associated with OS similar to findings by Jaudah and
colleagues, who find no correlation between expression of
p21 and overall survival in colorectal cancer [135].
Among the four markers associated with limitless rep-
licative potential, cylin D1 and p53 are the most consist-
ently associated with OS. Cyclin D1 is an important cell
cycle regulator, being one of the cyclin-dependent ki-
nases, and is controlled from chromosomal region 11q13,
which is known to undergo amplification in several can-
cers, including head and neck cancer. Results again
showed a significantly increased likelihood of poor prog-
nosis for ESCC patients when positive for this biomarker.
For p53, the finding that positive expression represents a
favorable prognostic feature is consistent with its tumor
suppressor function. For Ki-67, a proliferation-associated
nuclear protein, only one of five included studies identi-
fies a significant association, failing to support a prognos-
tic role in EC patients, whereas HER-2, a member of
epidermal growth factor receptor family, shows associ-
ation with OS in EADC.
In terms of functional capabilities, markers, involved
in facilitating tissue invasion and metastasis, include
E-cadherin, whose disappearance is a hallmark of
epithelial-mesenchymal transition [136]. E-cadherin is
down-regulated in several epithelial malignancies [137].
Ten eligible studies, analyzed here by random effects mod-
eling, further support the prognostic role of E-cadherin
loss in OS.
SCC-Ag is a tumor-associated antigen and was origin-
ally isolated from a squamous cell carcinoma (SCC). Five
studies relating to prognosis in ESSC do not reveal
elevated SCC-Ag to be associated with poor survival.
The current findings are in agreement with reports forSCC-Ag in patients with cancers of the cervix and lung
[138,139]. CRP has been shown to be of prognostic value
in many malignancies [140]. We further show that high
CRP expression is significantly correlated with poor sur-
vival in EC. We report on five studies concerning serum
Hb levels, four of which find that a reduced Hb level has a
significant relationship with decreased survival. Overall,
the evidence suggests that serum Hb measurement is a
significant prognostic marker, but the strength of correl-
ation is poor.
The strength of our study lies in the broad, unbiased
survey of the available esophageal cancer literature and
application of standard systematic review and meta-
analysis methods to objectively identify manuscripts with
robust data for summarization. However, there are sev-
eral limitations inherent to our study. By not evaluating
redundant study data, we attempted to avoid repeated
inclusion of manuscripts from different publications,
and focus on studies assessing prognostic markers with
standard oncological endpoints of overall survival, while
excluding studies with evaluation of recurrence. This study
is also limited from the perspective that, for 13 of the eli-
gible markers, summary data across outcome was derived
from association data presented in more than four studies,
excluding markers represented in included studies fewer
than five.
For the included studies, the across-study heterogeneity
in the execution of test methods as well as categorization
and statistical adjustments for the clinicopathologic factors
included in our multivariate analysis may contribute to
measurement error of the biomarker to outcome as-
sociations. Although most of the authors corrected for
established prognostic variables, variations included in
adjustment method contribute to inaccuracy related to
risk estimation. Variability in assessment of marker ex-
pression and cuto-ff point selection across studies may
be considered as a potential source of bias. For majority
of markers, selection of cut-point to categories marker
expression was arbitrary and varied among studies even
for the same marker using the same kind of test method.
For markers included more than ten studies (VEGF,
cyclin D1, p53) for overall survival estimate, stratified ana-
lyses was performed according to cut-point value. For
VEGF, the choice of the cutoff value for VEGF positivity
in IHC (14 studies) varied from 10 to 80% among studies.
Seven studies used 10% with combined HR 2.03 (95% CI,
1.51-2.73), this finding is consistent with the pooled HR
1.80 (95% CI, 1.51-2.14). In the other groups, the number
of studies eligible for estimate is less than five and hetero-
geneity are significant, so the results should be considered
with caution. For cyclin D1 and p53, the situation is simi-
lar. Only 10% group with five or more studies eligible for
meta-analysis. Adoption of consensus cutpoints across the
esophageal cancer community could facilitate replication
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are needed to define the precise prognostic value of
biomarkers.
Publication bias remains a problem in assessing the
validity of research studies. Although the power to de-
tect publication bias is reduced when fewer studies are
included, when using the Egger’s test on our meta-
analysis, 10 of 13 biomarkers do not show evidence that
publication bias significantly influenced the results. How-
ever, analysis of 3 biomarkers (p21, HER-2 and CRP) did
display significant publication bias. This may possibly be
due to missing data because of unpublished studies. Our
review takes into account only published studies. We did
not search unpublished studies and abstracts because the
methodology we used requires data that are usually only
available in full publication studies. Missing information
may reflect a negative or more conservative correlation
between markers and survival, which could lower the sig-
nificance of markers expression as a predictor of mortality
[141]. Thus, the results for p21, HER-2 and CRP should
be treated with considerable caution.
Conclusions
Research in EC has identified a multitude of molecular
markers with a significant role in predicting outcome.
In this review, despite the inherent limitations of meta-
analysis on prognostic literature, we identify several
biomarkers of particular interest that appear to carry
prognostic significance. Of 13 biomarkers analyzed, we find
VEGF, cyclin D1, Ki-67, and SCC-Ag appeared to hold po-
tential as predictors of outcome in ESCC; COX-2 and
HER-2 in EADC; and p21, p53, CRP and Hb in EC. Several
biomarkers did not have sufficient data for determination
of prognostic value in esophageal cancers. There is a need
for biomarker expression and validation of these potential
markers in large cohorts of patients. Additional studies
with consistent methodology are needed to define the pre-
cise prognostic value of biomarkers.
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